Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience. Our management team has deep expertise and a track record of building exceptional life science companies. We have developed a product engine that may transform treatment for a wide range of diseases, and we have multiple clinical and preclinical product programs. Our pipeline includes VY-AADC01 for Parkinson’s disease, which is in an ongoing Phase 1b study, as well as preclinical programs VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich’s ataxia, VY-HTT01 for Huntington's disease, VY-TAU01 for frontotemporal dementia and Alzheimer’s disease and VY-NAV01 for severe, chronic pain.
Voyager is committed to advancing the field of AAV gene therapy by innovating and investing in areas such as vector optimization and engineering, dosing techniques, as well as process development and production.
We have broad strategic collaborations with Genzyme, a Sanofi company, and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California, San Francisco and Stanford University to access relevant technology and data.
Headquartered in Cambridge, Mass., Voyager was launched in 2014 with $45 million in Series A venture capital financing from Third Rock Ventures.